Literature DB >> 15103897

[Campylobacter fetus subsp. fetus sepsis: a case report and review of the literatures in Japan].

Shukuko Saito1, Toshio Naito, Junko Kukino, Tetsu Okumura, Sakae Sekiya, Hiroshi Isonuma, Kazuyoshi Watanabe, Takashi Dambara, Yasuo Hayashida.   

Abstract

We report a 32-year-old female with eating disorder whose body weight was only 20 kg. She was admitted to the hospital with severe low nutrition, low proteinemia, liver dysfunction, hypokalemia and hypoglycemia. On the third hospital day, she had a high fever and Campylobacter fetus subsp. fetus (C. fetus) was isolated from the blood. After treatment with meropenem (1 g/day) intravenous drip injection, her condition improved. C. fetus sepsis is not common disease in Japan. A review of 37 cases of this disease in Japan revealed that the age range of adult patients was 20 to 60 years old. The male-to-female ratio was 4.6 to 1.0. Seventy-eight percent of the patients had underlying diseases which were composed of 11 patients with liver disease, 6 patients with blood dyscrasia and some with diabetes mellitus, heart disease, other malignant tumor and collagen disease. There was no case with eating disorder. All apparent sources of infection in Japan originate from eating raw food. Gastrointestinal symptoms were observed in only 16% of the patients. Recent recommendations for the treatment of C. fetus sepsis are to use gentamicin, imipenem and meropenem. Some strains of C. fetus have resistance to erythromycin, ciprofloxacin. The mortality of this infection is 14% in Japan.

Entities:  

Mesh:

Year:  2004        PMID: 15103897     DOI: 10.11150/kansenshogakuzasshi1970.78.70

Source DB:  PubMed          Journal:  Kansenshogaku Zasshi        ISSN: 0387-5911


  1 in total

1.  Clinical and epidemiological analysis of Campylobacter fetus subsp. fetus infections in humans and comparative genetic analysis with strains isolated from cattle.

Authors:  Robert Escher; Colette Brunner; Niklaus von Steiger; Isabelle Brodard; Sara Droz; Carlos Abril; Peter Kuhnert
Journal:  BMC Infect Dis       Date:  2016-05-14       Impact factor: 3.090

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.